Tag: Cabiralizumab

January 24, 2018

Five Prime Announces Proposed Public Offering of Common Stock

Five Prime Therapeutics (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that...
April 10, 2017

Five Prime Completes Enrollment of Phase 2 Trial

Five Prime Therapeutics finished enrollment for an ongoing Phase 2 trial of Cabiralizumab treating Pigmented Villonodular Synovitis.